Kreido’s STT® Reactor System to Be Utilized by Huntsman
News Oct 07, 2005
Kreido Laboratories has announced that Huntsman has purchased its STT® Reactor System.
Kreido Laboratories has pioneered a system for the manufacturing of chemicals, pharmaceuticals and other biological products.
The STT® system is designed to improve selectivity, increase yields and initiate chemistries.
The technology improves the efficiency, quality and speed of many chemical processes and facilitates continuous manufacturing.
The Huntsman transaction represents Kreido™s entry into the European marketplace.
Kreido has successfully applied the STT® Reactor System to the manufacturing of chemicals.
“We believe Huntsman will greatly benefit from our technology, as the systems ability to mitigate mass transfer limitations and accelerate reactions is well known,” said Kreido Laboratories Managing Director Ben Binninger.
“Numerous STT® Reactor Systems are already operating in the United States, and we are certainly delighted to expand our reach into Europe.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019